04/22/2026
🌟 Orforglipron (Foundayo) – A New Era in Metabolic Health
We are excited to share a major milestone in the fight against obesity, diabetes, and related chronic diseases.
Orforglipron (Foundayo) has now been approved for:
• ✅ Obesity
• ✅ Overweight with comorbid disorders
This is not just another medication. It represents a meaningful step forward in how we manage metabolic health.
______________
💡 What makes Orforglipron (Foundayo) special?
This medication does far more than help with weight loss. It offers a powerful combination of benefits:
• 🧭 Reduces body weight significantly
• 🩸 Mitigates diabetes and improves glycemic control
• 🛡️ Prevents the progression of prediabetes to diabetes
• ❤️ Independent cardioprotective effects – protects the heart directly
• 🧠 Independent kidney protective effects – supports renal health
These effects are independent of weight loss, making Orforglipron a true multi-organ metabolic therapeutic agent.
______________
📚 Resources We’ve Created for You
To ensure this important information reaches everyone – not just medical practitioners – we have developed educational content in multiple languages.
📝 Blogs (3 languages)
English
English: https://ksphealth.org/foundayo-orforglipron-weight-loss/ [L]
Hindi: https://ksphealth.org/foundayo-orforglipron-weight-loss-hindi/
Tamil: https://ksphealth.org/foundayo-orforglipron-weight-loss-tamil/
🎥 Videos (2 languages)
Tamil : https://www.youtube.com/watch?v=SBaWTiviRF4
English : https://www.youtube.com/watch?v=f14NNL-z5Ms
______________
🌍 A Request to You
We deeply appreciate your support. Please help us spread the word – not just to doctors and healthcare professionals, but to patients, families, and communities.
💬 Share this message.
📢 Share the blogs.
🎬 Share the videos.
Together, we can create awareness, reduce stigma around obesity treatment, and help people access better metabolic care.
______________
🙏 With gratitude
Thank you for being part of this mission.
Warm regards,
Team KSP Health
The FDA Just Approved This Pill for Obesity — Here's What Happens Next